TG Therapeutics reported Q4 2025 total revenue of USD 192.6 million and FY 2025 total revenue of USD 616.3 million. Q4 product revenue, net was USD 189.1 million and FY product revenue, net was USD 606.9 million, primarily driven by BRIUMVI U.S. net product revenue of USD 182.7 million in Q4 (20% Q/Q growth) and USD 594.1 million in FY (92% Y/Y growth). Q4 license, milestone, royalty and other revenue was USD 3.5 million and FY was USD 9.4 million. Q4 2025 R&D expense was USD 41.2 million and SG&A expense was USD 62.7 million; FY 2025 R&D was USD 160.2 million and SG&A was USD 232.0 million. Q4 net income was USD 23.0 million and FY net income was USD 447.2 million, which included a non-recurring income tax benefit of USD 339.8 million related to the release of a deferred tax asset valuation allowance in Q3 2025. Cash, cash equivalents and investment securities were USD 199.5 million as of December 31, 2025. For 2026, TG Therapeutics raised guidance and targets total global revenue of USD 875-900 million, including BRIUMVI U.S. net product revenue of USD 825-850 million, and Q1 2026 BRIUMVI U.S. net product revenue of USD 185-190 million. Operationally, the company highlighted BRIUMVI’s expansion with partner Neuraxpharm, with approvals in the EU, UK, Switzerland, Australia, Kuwait and the UAE, and progress in its pipeline including approximately 75% enrollment in the Phase 3 subcutaneous ublituximab program, completion of enrollment in the Phase 3 ENHANCE trial evaluating a consolidated IV dosing regimen (topline data expected mid-year 2026), and continued Phase 1 enrollment of azer-cel in progressive MS (preliminary data expected in H2 2026). TG Therapeutics also said it completed its USD 100 million share repurchase program in Q3 2025 and authorized an additional USD 100 million repurchase program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260700PRIMZONEFULLFEED9661856) on February 26, 2026, and is solely responsible for the information contained therein.
Comments